Olympus Launches EndoClot Portfolio in Europe and EMEA

Olympus announces the launch of EndoClot® Adhesive (ECA), EndoClot® Polysaccharide Hemostatic Spray (PHS) and EndoClot® Submucosal Injection Solution (SIS) in the Europe, Middle East and Africa (EMEA) region.

This innovative portfolio is developed by EndoClot Plus, Inc. (EPI), which expanded its distribution agreement with Olympus from the U.S. to EMEA in December 2022.

We are excited to expand our global partnership with EndoClot Plus, Inc. The addition of their solutions to our portfolio allows us to strengthen our commitment to our customers as a full gastrointestinal solution provider for advanced therapeutic procedures. Endoscopic resection and associated bleeding management are among Olympus’ core competencies. By contributing to safe treatment in gastrointestinal procedures, we aim to improve patient outcomes and hereby elevate the standard or care.

Stefanie Kaufung, EMEA Business Unit Manager GI EndoTherapy at Olympus

“EndoClot SIS supports me to have a long-lasting mucosal lift with high elevation to create effective mucosal separation and enabling precise ESD/EMR; whereas EndoClot PHS and ECA can provide expanded options to address emergent and residual bleeding or prevent re-bleeding at resection sites”, says Dr. David Tate, Medical Doctor at University Hospital of Gent, Belgium.

EndoClot ECA is a single-use medical device to seal lesions, consisting of Hemostatic Polymer (AHP). AHP is a durable hemostatic polymer due to its resistance to acids and bases in the GI-tract. Since it is a durable adhesive, it is recommended to be used only at the end of the procedure to stop and control oozing bleeding, prevent re-bleeding and protect the wound from irritation by acids and bases.

EndoClot PHS and EndoClot SIS are both based on the EndoClot Absorbable Modified Polymer (AMP®) technology. The starch-derived AMP technology has demonstrated an excellent safety profile. The EndoClot AMP particles work by absorbing water from blood. The dehydration process causes a high concentration of platelets, red blood cells and coagulation proteins, which helps accelerate the body’s clotting cascade. AMP particles are biocompatible, bioabsorbable, non-pyrogenic, starch derived and contain no animal or human components.